Lymphoma, Large B-Cell, Diffuse Clinical Trial
Official title:
ChiCGB Versus BEAM With Autologous Stem-Cell Transplantation in High-risk Hodgkin and Non-Hodgkin Lymphoma - A Prospective, Multi-centered, Randomized Clinical Trial
High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) plays a vital role in treating high-risked or relapsed/refractory lymphoma. Our previous study showed chidamide combined with cladribine, gemcitabine, and busulfan (ChiCGB) as conditioning therapy improved the survival of these patients. So we designed this trial to verify if ChiCGB were better than BCNU, etoposide, cytarabine, and melphalan (BEAM). Patients with diffuse large B cell or extra-nodal NK/T cell Lymphoma who consent to this study will be randomized into the trial group who receive ChiCGB or the control group whom receive BEAM. Patients will be followed for up to 2 years after the hematopoietic cell transplantation (HCT).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03977623 -
Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
|
||
| Recruiting |
NCT02428751 -
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
|
Phase 3 | |
| Completed |
NCT02555267 -
Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma
|
||
| Active, not recruiting |
NCT02364050 -
Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM
|
||
| Terminated |
NCT00529503 -
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
|
Phase 2 | |
| Terminated |
NCT02413489 -
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
|
Phase 2 | |
| Completed |
NCT02086604 -
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
Phase 1 | |
| Completed |
NCT01421524 -
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT03600363 -
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
|
Phase 2 | |
| Recruiting |
NCT03646422 -
AEDV Registry of Primary Cutaneous Lymphoma
|
||
| Recruiting |
NCT04446962 -
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03241017 -
Durvalumab in DLBCL After Autologous Transplant
|
Phase 2 | |
| Recruiting |
NCT02931201 -
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma
|
N/A | |
| Recruiting |
NCT02928861 -
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
|
N/A | |
| Terminated |
NCT02592876 -
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00849147 -
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
|
Phase 2 | |
| Completed |
NCT00822432 -
Coproporphyrine Isomers and Methotrexate Elimination
|
N/A | |
| Completed |
NCT03682796 -
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04982471 -
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
|
||
| Completed |
NCT03744676 -
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
|
Phase 2 |